4KB logo

Krystal Biotech BST:4KB Stock Report

Last Price

€145.00

Market Cap

€4.7b

7D

0%

1Y

-10.5%

Updated

13 Mar, 2025

Data

Company Financials +

4KB Stock Overview

A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. More details

4KB fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance4/6
Financial Health6/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Krystal Biotech, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Krystal Biotech
Historical stock prices
Current Share PriceUS$145.00
52 Week HighUS$190.65
52 Week LowUS$141.90
Beta0.87
1 Month Change0%
3 Month Changen/a
1 Year Change-10.49%
3 Year Changen/a
5 Year Change334.13%
Change since IPO716.44%

Recent News & Updates

Recent updates

Shareholder Returns

4KBDE BiotechsDE Market
7D0%-1.2%-1.6%
1Y-10.5%-13.4%13.8%

Return vs Industry: 4KB exceeded the German Biotechs industry which returned -13.4% over the past year.

Return vs Market: 4KB underperformed the German Market which returned 13.8% over the past year.

Price Volatility

Is 4KB's price volatile compared to industry and market?
4KB volatility
4KB Average Weekly Movementn/a
Biotechs Industry Average Movement9.2%
Market Average Movement5.3%
10% most volatile stocks in DE Market12.0%
10% least volatile stocks in DE Market2.7%

Stable Share Price: 4KB's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine 4KB's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2016275Krish Krishnanwww.krystalbio.com

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb.

Krystal Biotech, Inc. Fundamentals Summary

How do Krystal Biotech's earnings and revenue compare to its market cap?
4KB fundamental statistics
Market cap€4.72b
Earnings (TTM)€81.94m
Revenue (TTM)€266.98m

57.6x

P/E Ratio

17.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4KB income statement (TTM)
RevenueUS$290.52m
Cost of RevenueUS$20.06m
Gross ProfitUS$270.45m
Other ExpensesUS$181.30m
EarningsUS$89.16m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)3.10
Gross Margin93.09%
Net Profit Margin30.69%
Debt/Equity Ratio0%

How did 4KB perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/13 04:00
End of Day Share Price 2025/01/27 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Krystal Biotech, Inc. is covered by 21 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Caroline PalomequeBerenberg
Alec StranahanBofA Global Research
Justin ZelinB. Riley Securities, Inc.